MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$1,393K
Free Cash flow
$12,310K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sales of short-ter...
    • Proceeds from stock option exerc...
    • Depreciation and amortization
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term marketab...
    • Cost of sales
    • Selling expense
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net sales
66,551 64,453 185,149 NaN
Cost of sales
18,155 18,263 52,800 NaN
Gross profit
48,396 46,190 132,349 NaN
Selling expense
12,800 12,162 37,272 NaN
Marketing expense
1,715 1,272 3,758 NaN
Administrative expense
7,963 6,975 21,268 NaN
Finance expense
3,184 2,718 8,322 NaN
Management information systems expense
899 698 2,043 NaN
Research and development expense
1,423 1,069 2,970 NaN
Process engineering expense
1,002 802 1,828 NaN
Regulatory and clinical expense
1,635 1,662 5,808 NaN
Restructuring expense
NaN 0 NaN NaN
Other (income) expense, net
-2,096 -3,250 -6,928 NaN
Net income
15,679 15,582 17,362 24,790
Depreciation and amortization
2,623 2,605 2,613 5,200
Stock-based compensation
2,092 2,096 1,740 3,990
Amortization of issuance costs on convertible senior notes
222 220 653 NaN
Non-cash investment income
102 NaN NaN NaN
Provision for inventory write-downs
761 768 863 1,030
Provision (benefit) for deferred income taxes
NaN 2,312 NaN NaN
Loss on divestitures
NaN 0 NaN NaN
Provision for credit losses
0 362 118 337
Fair value adjustments to contingent consideration obligations
NaN NaN 0 0
Unrealized loss on equity investments
NaN -535 NaN NaN
Foreign currency transaction effect on income
-71 97 -200 279
Accounts receivable
2,481 1,544 -3,896 5,299
Inventory and other deferred costs
1,392 418 6,805 NaN
Prepaid expenses and other assets
-1,038 -787 37 -1,676
Non-cash interest expense and end of term accretion expense
NaN NaN NaN 2,589
Accounts payable and other liabilities
-2,340 -1,129 6,577 -1,250
Inventory and other deferred costs
NaN NaN NaN 3,454
Accrued interest
-1,078 1,078 719 NaN
Net cash provided by operating activities
15,093 23,157 28,764 29,330
Purchases of short-term marketable securities
150,866 598,314 25,166 17,849
Purchases of property and equipment
2,783 1,777 2,281 2,725
Payments related to acquisitions, net of cash acquired
45 1,804 0 95
Proceeds from sales of short-term marketable securities
140,573 585,070 NaN NaN
Net cash used in investing activities
-13,121 -16,825 -27,447 -20,669
Proceeds from stock option exercises
2,952 2,166 1,585 3,072
Proceeds from issuance of convertible senior notes, net of issuance costs paid of 3,234
NaN 0 NaN NaN
Deferred payments for acquisitions
0 0 0 1,433
Costs paid related to issuance of convertible senior notes-Convertible Senior Notes
NaN 0 NaN NaN
Payment of withholding taxes in connection with net settlement of equity awards
460 1,216 0 605
Common stock cash dividend paid
5,711 4,537 4,535 9,037
Net cash used in financing activities
-3,219 -3,587 -2,950 -8,003
Effect of exchange rate changes on cash and cash equivalents
-146 5 -50 909
Net increase (decrease) in cash and cash equivalents
-1,393 2,750 -1,683 1,567
Cash and cash equivalents at beginning of period
28,244 25,494 2,589 NaN
Cash and cash equivalents at end of period
26,851 28,244 25,494 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net sales$66,551K Gross profit$48,396K Canceled cashflow$18,155K Net income$15,679K Depreciation andamortization$2,623K Stock-based compensation$2,092K Prepaid expenses andother assets-$1,038K Provision for inventorywrite-downs$761K Amortization of issuancecosts on convertible...$222K Foreign currencytransaction effect on income-$71K Canceled cashflow$32,717K Cost of sales$18,155K Net cash provided byoperating activities$15,093K Canceled cashflow$7,393K Selling expense$12,800K Administrative expense$7,963K Finance expense$3,184K Other (income)expense, net-$2,096K Marketing expense$1,715K Regulatory and clinicalexpense$1,635K Research and developmentexpense$1,423K Process engineeringexpense$1,002K Management informationsystems expense$899K Net increase(decrease) in cash and cash...-$1,393K Canceled cashflow$15,093K Proceeds from sales ofshort-term marketable...$140,573K Proceeds from stockoption exercises$2,952K Accounts receivable$2,481K Accounts payable andother liabilities-$2,340K Inventory and otherdeferred costs$1,392K Accrued interest-$1,078K Non-cash investmentincome$102K Net cash used ininvesting activities-$13,121K Canceled cashflow$140,573K Net cash used infinancing activities-$3,219K Effect of exchange ratechanges on cash and cash...-$146K Canceled cashflow$2,952K Purchases of short-termmarketable securities$150,866K Purchases of property andequipment$2,783K Payments related toacquisitions, net of cash...$45K Common stock cashdividend paid$5,711K Payment of withholdingtaxes in connection...$460K

LEMAITRE VASCULAR INC (LMAT)

LEMAITRE VASCULAR INC (LMAT)